BACKGROUND: Mild to moderate musculoskeletal trauma is a common cause for an emergency room visit, and frequent pain is one of the cardinal symptoms of consultation. The objective of this study is to assess the perception of a single subcutaneous dose of 50 mg tramadol for pain management in patients with mild to moderate musculoskeletal trauma, likewise to appraise the perception of pain by subcutaneous injection.
INTRODUCTION
Acute pain is one of the leading causes of visits to the emergency department (ED), [1] [2] [3] [4] including a large percentage that is secondary to mild to moderate musculoskeletal trauma, [5] representing an important ED overcrowding and extended service times associated with poor control of disabling pain. [6] [7] [8] The analgesic routes in health services are defi ned as enteral and parenteral; within the latter, the subcutaneous (SC) route has been insufficiently studied in urgent patients.
Hence, we seek to know if SC tramadol is perceived as effective by patients with mild to moderate musculoskeletal trauma admitted in a defi ned period in our ED.
The study aimed to evaluate the effectiveness of SC tramadol in patients with mild to moderate musculoskeletal trauma based on the verbal numerical pain scale at twenty and sixty minutes, so as to assess whether the pain perceived by SC injection supports its administration in relation to the pain perceived by the trauma.
METHODS
Clinica Las Vegas in Medellin, Colombia, is a tertiary care complexity center with 51 000 visits per year. Approximately, 20% of visits correspond to mild to moderate musculoskeletal trauma due to workplace, traffic-related, domestic, or sports accidents. In September and October, 2013, 77 patients who met inclusion criteria were attended. The patients included those with mild to moderate musculoskeletal trauma aged over 18 years. They were ED walk-in patients who did not require stitches and had no exclusion criteria: patients who were previously medicated with analgesics before consulting the ED or that had been consuming painkillers for some pathology, epilepsy, liver disease, tramadol allergy, trauma requiring hospitalization or intravenous medication according to the opinion of treating physician, or pregnancy.
This study was approved by the ethical committee of the clinic prior to verbal patient consent and verifi cation of tramadol blister for subcutaneous delivery authorized by the Instituto Nacional de Vigilancia de Medicamentos (INVIMA). A single subcutaneous dose (50 mg) was supplied. The injection was provided by nursing assistant using hypodermic syringe of insulin in the periumbilical area following the same technique of insulin delivery. For each patient, a record consisting of a checklist of inclusion and exclusion criteria and boxes to record the number given by the patient in the verbal pain scale (0 no pain; 10 severe pain) to the injury perceived by the trauma at 20 and 60 minutes after the administration of tramadol. The same pain scale was used to record the value perceived by subcutaneous injection. Likewise, the need for rescue medication was assessed.
Study type
An observational prospective registry, or the questionnaire to pain scales (initial trauma pain and subcutaneous pain) was designed by a blinded doctor on the collection of data. Statistical analysis was performed by SPSS version 18, and Friedman's test was used to compare pairwise results.
RESULTS
In September and October, 2013, 77 patients were included in the registry. In this series, 74% were men (Table 1) . Their mean age of the patients was 31 years musculoskeletal trauma, 13% with sprain, 11% with acute low back pain, and 10% with closed fractured fi ngertips. The average pain according to the verbal scale at baseline was 8, after 20 minutes was 3; and following 60 minutes was 2 ( Table 2 ). Only 6.5% of the patients required a second medication for persistent pain. 88% of the patients revealed three or less on the verbal pain scale during application of the subcutaneous medication (Table 3) .
DISCUSSION
Tramadol is a weak opioid with low affinity for receptors, but with activity in monoaminergic pathways by inhibiting the reuptake of norepinephrine and increasing the release of serotonin, providing an analgesic profile with fewer side-effects than pure opioids, making it more tolerable. [9, 10] Classically, tramadol has been used parenterally with the presumption of greater analgesic potency bioavailability; however, there have been reported side-effects, most frequent nausea (6.1%), dizziness (4.6%), drowsiness (2.4%), tiredness/ fatigue (2.3%), sweating (1.9%), vomiting (1.7%) and dry mouth (1.6%), less common pruritus, subcutaneous nodules and seizures. [11] [12] [13] [14] The security profile of single doses or less than 24 hours administration is similar, leaving tramadol as a safe drug that can be used differently for rectal, intravenous, sublingual, muscular, oral, regional analgesia or subcutaneous infusion. These routes have been explored in postoperative pain, labor, abdominal pain, trauma and chronic conditions such as pain due to cancer and neuropatic pain. [15] [16] [17] [18] The subcutaneous route is used in emergency s e r v i c e s b e c a u s e o f i t s e a s y p r e p a r a t i o n a n d administration, especially because difficult vascular access may delay patient care. [19, 20] A single 50 mg-SC dose of tramadol is a useful alternative in patients presenting to the ED for mild to moderate musculoskeletal trauma, with a significant reduction in pain on the verbal scale, with a success rate of 50% at 20 minutes and 75% at 60 minutes and a low incidence of adverse events or complications. Other studies [21] investigated subcutaneous tramadol for acute pain in the ED because of a broader range of causes. We focused on musculoskeletal causes since they are very common in our ED.
A subcutaneous alternative is safe and fast and helps to reduce the rate of unnecessary intravenous medication and to assist in patient's satisfaction in managing pain. [22] [23] [24] [25] In conclusion, a single subcutaneous 50 mg dose of tramadol is a useful and safe alternative in patients presenting to the emergency department for mild to moderate musculoskeletal trauma, with a significant reduction in pain at 20 and 60 minutes after application. Pain perception of the injection by patients supports its application in the emergency department.
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